Please enable Javascript
Advanced Renal Cell Carcinoma
Advertisement
Integrative Approaches in Kidney Cancer Biomarker Research
David Braun, MD, PhD
Advanced Renal Cell Carcinoma
|
April 22, 2024
Drs. Braun and Beckermann stress the importance of adopting an integrative approach to biomarker-based research in RCC.
View More
Kidney Cancer Biomarker Insights: JAVELIN Renal 101
David Braun, MD, PhD
Advanced Renal Cell Carcinoma
|
April 22, 2024
Drs. Braun and Beckermann review JAVELIN Renal 101, focusing on the impact of avelumab and axitinib treatment on RCC.
View More
Transcriptomic Insights: Revolutionizing Kidney Cancer Biomarker Integration
David Braun, MD, PhD
Advanced Renal Cell Carcinoma
|
April 22, 2024
Drs. Braun and Beckermann discuss the evolving significance of sarcomatoid histology in guiding treatment decisions for RCC.
View More
Beyond LAG-3: Promising Immuno-Oncology Targets in Kidney Cancer
Michael B. Atkins, MD
Advanced Renal Cell Carcinoma
|
April 11, 2024
Drs. Atkins and Beckermann weigh the potential of targeting Tregs in RCC treatment, particularly in relation to PD-1 therapy.
View More
The Potential Synergistic Power of LAG-3 and PD-1 in Kidney Cancer
Michael B. Atkins, MD
Advanced Renal Cell Carcinoma
|
April 11, 2024
Drs. Atkins and Beckermann consider biomarkers for patient selection for LAG-3 inhibition and increasing cure rates in RCC.
View More
Redefining Immune Strategies: LAG-3 With PD-1 in Kidney Cancer
Michael B. Atkins, MD
Advanced Renal Cell Carcinoma
|
April 11, 2024
Drs. Atkins and Beckermann discuss LAG-3 as a novel checkpoint inhibitor combined with anti-PD-1 for kidney cancer.cC
View More
Rechallenge With PD-1/L1 Inhibitors Ineffective for mccRCC
Emily Menendez
Advanced Renal Cell Carcinoma
|
April 10, 2024
The results of this study are similar to previous data from the phase 3 CONTACT-03 trial.
Read More
Pazopanib Shows No DFS Improvement for Metastatic RCC
Katy Marshall
Advanced Renal Cell Carcinoma
|
April 3, 2024
A randomized, phase 3 trial evaluated the potential of pazopanib versus placebo to improve DFS in patients with mRCC.
Read More
Cytoreductive Nephrectomy With, Without ICIs for mRCC
Emily Menendez
Advanced Renal Cell Carcinoma
|
March 22, 2024
Data from the JAVELIN Renal 101, KEYNOTE-426, CheckMate 9ER, CLEAR, and IMmotion151 trials were reviewed.
Read More
CheckMate 214: Risk-Group Considerations and Combination Preferences
Daniel J. George, MD, FASCO
Advanced Renal Cell Carcinoma
|
March 6, 2024
Dr. George shares his expert opinion on the 8-year CheckMate 214 survival and durable response data in advanced RCC.
View More
How Does KEYNOTE-564 Open the Door For New Adjuvant Approaches?
Daniel J. George, MD, FASCO
Advanced Renal Cell Carcinoma
|
March 6, 2024
Dr. George provides an overview of the adjuvant pembro long-term data and the other adjuvant approaches being investigated.
View More
Analyzing Fianlimab, Cemiplimab for Patients With ccRCC
Katy Marshall
Advanced Renal Cell Carcinoma
|
February 21, 2024
Researchers analyzed the data from patients who received anti–LAG-3 and anti–PD-1.
Read More
CheckMate 214: Long-Term Survival Implications, Treatment Ramifications for Favorable-Risk Patients
Saby George, MD, FACP
Advanced Renal Cell Carcinoma
|
March 7, 2024
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
View More
CheckMate 67T: Subcutaneous Nivolumab for Advanced or Metastatic Clear Cell RCC
Saby George, MD, FACP
Advanced Renal Cell Carcinoma
|
March 7, 2024
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
View More
KEYNOTE-564, CheckMate 9ER, and More: Where Do We Stand With Advanced and Metastatic RCC?
Thomas Powles, MBBS, MRCP, MD
Advanced Renal Cell Carcinoma
|
March 7, 2024
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
View More
Looking Ahead in RCC: Belzutifan, Triplets, Treatment Combinations, and More
Rana McKay, MD
Renal Cell Carcinoma
|
February 8, 2024
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
View More
CheckMate 67T and the Potential of Subcutaneous Nivolumab Administration
Rana McKay, MD
Renal Cell Carcinoma
|
February 8, 2024
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
View More
CheckMate 9ER: What Is the Impact for RCC?
Rana McKay, MD
Renal Cell Carcinoma
|
February 8, 2024
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
View More
Panel Shares Thoughts on RCC Data: CheckMate 914, 214 and IMDC Selection Criteria
Rana McKay, MD
Renal Cell Carcinoma
|
February 8, 2024
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
View More
Panel Discussion on OS Data From KEYNOTE-564 Study and Post-Relapse Treatment Selection
Rana McKay, MD
Renal Cell Carcinoma
|
February 8, 2024
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
View More
Load More
Advertisement
Advertisement
Advertisement